Newsroom 2011

2011 Releases

CSL partners US agency on key study to prevent common causes of abnormalities in newborns
CSL Limited announced today that it is partnering with the world’s largest health research agency, the US National Institutes of Health (NIH), to study a potential new treatment for the prevention of congenital CMV infection, one of the most common known causes of congenital (i.e., present at birth) abnormalities in the developed world. More.

CSL wins equal opportunity award for onsite childcare centre
CSL Limited has been recognised as one of Australia’s most outstanding equal opportunity employers by the Federal Government for its work in establishing an innovative onsite childcare centre at its corporate headquarters in Melbourne. More.

CSL announces A$900m share buy-back
CSL Limited today announced a new on-market buy-back of up to A$900 million of CSL shares. More.

CSL Biotherapies - Response to News Reports on FDA Inspections
CSL Biotherapies wishes to clarify that it has not received any new letters or warnings from the US Food and Drug Authority (FDA) or the Australian Therapeutic Goods Administration (TGA) concerning its compliance with current Good Manufacturing Practice (cGMP). More.

CSL Biotherapies - Restricted Supply of BenPen™
CSL Biotherapies has advised hospitals that BenPen™ (Benzylpenicillin) is on restricted supply in Australia and New Zealand until December 2011. More.

CSL opens $4.8m workplace childcare centre
CSL Limited and the Early Childhood Management Services (ECMS) today proudly opened the Thinking Kids Children’s Centre, an early childhood education and care centre at CSL’s Parkville site in Victoria. More.

Full Year Results Announcement for 2010/11
CSL Limited today reported a net profit after tax of $941 million for the twelve months ended 30 June 2011, down $112 million or 11% when compared to the prior comparable period. More.

CSL Announces Changes to the Board
CSL Limited (ASX:CSL) today announced that Chairman, Miss Elizabeth Alexander, AM, and Director, Mr David Simpson, have indicated their intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 19 October 2011. More.

CSL Subsidiary Donates von Willebrand Factor / Factor VIII to World Federation of Hemophilia
CSL Behring gives more than 1 million units of VWD medication via WFH’s Global Alliance for Progress program as part of its 3-year commitment to the organization. More.

CSL Biotherapies Statement on FDA Warning Letter for GMP issues at Australian Influenza Vaccine Facility
Today the US Food and Drug Administration (FDA) published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies, a division of CSL Limited. The FDA regulates the manufacture, marketing and distribution of CSL Biotherapies’ influenza vaccine, Afluria®, in the US market. More.

CSL welcomes historic pandemic agreement and pledges further support for developing countries
CSL Biotherapies welcomes news of a decision by the World Health Assembly to adopt the Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits. More.

Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
CSL Limited (ASX:CSL) subsidiary, CSL Behring, today issued a press release regarding advances that it is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with haemophilia A and B. More.

Press Release - CSL fully supports the ATAGI recommendations for use of influenza vaccine in children
Today, the Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement of advice for immunisation providers regarding the administration of 2011 trivalent seasonal influenza vaccines. More.

Half-year results announcement for 2010/11
CSL Limited today announced its first half result for period ended 31 December 2010. More.

© 2017 CSL Limited